Current therapies targeting the VEGF/VEGFR pathway, including VEGF or VEGFR neutralizing antibodies and TKIs, have demonstrated substantial efficacy in patients with NSCLC [194]. This evidence concerns the gene KDR and non-small cell lung carcinoma.